收费全文 | 24398篇 |
免费 | 1296篇 |
国内免费 | 75篇 |
耳鼻咽喉 | 458篇 |
儿科学 | 876篇 |
妇产科学 | 452篇 |
基础医学 | 3093篇 |
口腔科学 | 593篇 |
临床医学 | 1570篇 |
内科学 | 6377篇 |
皮肤病学 | 796篇 |
神经病学 | 1842篇 |
特种医学 | 576篇 |
外科学 | 3724篇 |
综合类 | 157篇 |
一般理论 | 9篇 |
预防医学 | 2007篇 |
眼科学 | 511篇 |
药学 | 1320篇 |
中国医学 | 97篇 |
肿瘤学 | 1311篇 |
2023年 | 123篇 |
2022年 | 139篇 |
2021年 | 540篇 |
2020年 | 300篇 |
2019年 | 606篇 |
2018年 | 869篇 |
2017年 | 542篇 |
2016年 | 512篇 |
2015年 | 551篇 |
2014年 | 686篇 |
2013年 | 1027篇 |
2012年 | 1618篇 |
2011年 | 1823篇 |
2010年 | 910篇 |
2009年 | 715篇 |
2008年 | 1461篇 |
2007年 | 1586篇 |
2006年 | 1485篇 |
2005年 | 1480篇 |
2004年 | 1400篇 |
2003年 | 1198篇 |
2002年 | 1223篇 |
2001年 | 735篇 |
2000年 | 889篇 |
1999年 | 589篇 |
1998年 | 104篇 |
1997年 | 88篇 |
1996年 | 93篇 |
1995年 | 63篇 |
1994年 | 68篇 |
1993年 | 53篇 |
1992年 | 215篇 |
1991年 | 217篇 |
1990年 | 178篇 |
1989年 | 143篇 |
1988年 | 119篇 |
1987年 | 127篇 |
1986年 | 112篇 |
1985年 | 110篇 |
1984年 | 69篇 |
1983年 | 68篇 |
1982年 | 50篇 |
1981年 | 45篇 |
1979年 | 47篇 |
1978年 | 41篇 |
1977年 | 32篇 |
1974年 | 48篇 |
1973年 | 31篇 |
1971年 | 33篇 |
1970年 | 32篇 |
Autoinflammatory diseases constitute a family of disorders defined by aberrant stimulation of inflammatory pathways without involving antigen-directed autoimmunity. They may be divided into monogenic and polygenic types. Monogenic autoinflammatory syndromes are those with identified genetic mutations, such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), mevalonate kinase deficiency or hyperimmunoglobulin D syndrome, cryopyrin-associated periodic fever syndromes (CAPS), pyogenic arthritis pyoderma gangrenosum and acne (PAPA) syndrome, interleukin-10 and interleukin-10 receptor deficiencies, adenosine deaminase 2 deficiency and pediatric sarcoidosis. Those without an identified genetic mutation are known as polygenic and include systemic-onset juvenile idiopathic arthritis, idiopathic recurrent acute pericarditis, Behçet syndrome, chronic recurrent multifocal osteomyelitis and inflammatory bowel disease among others. Autoinflammatory disorders are defined by repeating episodes or persistent fever, rash, serositis, lymphadenopathy, arthritis and increased acute phase reactants, and thus may mimic infections clinically. Most monogenic autoinflammatory syndromes present in childhood. However, because of their infrequency, diverse and nonspecific presentation, and the relatively new genetic recognition, diagnosis is usually delayed. In this article, which is Part 1 of a two-part series, the authors update monogenic autoinflammatory diseases in children with special emphasis on imaging features that may help establish the correct diagnosis.
相似文献Autoinflammatory diseases are a family of disorders characterized by aberrant stimulation of inflammatory pathways without involvement of antigen-directed autoimmunity. They can be further divided in monogenic and polygenic types. Those without an identified genetic mutation are known as polygenic and include systemic-onset juvenile idiopathic arthritis, idiopathic recurrent acute pericarditis, Behçet syndrome, chronic recurrent multifocal osteomyelitis and inflammatory bowel disease among others. Autoinflammatory diseases are characterized by recurrent flares or persistent systemic inflammation and fever, as well as lymphadenopathy and cutaneous, abdominal, thoracic and articular symptoms. Although these syndromes can mimic infections clinically, the inflammatory lesions in autoinflammatory disorders are aseptic. However, because of their infrequency, varied and nonspecific presentation, and the new genetic identification, diagnosis is usually delayed. In this article, which is Part 2 of a two-part series, the authors review the main polygenic autoinflammatory diseases that can be seen in childhood, with special emphasis wherever applicable on imaging features that may help establish the correct diagnosis. However, the major role of imaging is to delineate organ involvement and disease extent.
相似文献Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi therapeutic, patisiran, on autonomic neuropathy manifestations in patients with hATTR amyloidosis with polyneuropathy in the phase III APOLLO study is reported. Patients received patisiran 0.3 mg/kg intravenously (n = 148) or placebo (n = 77) once every 3 weeks for 18 months. Patisiran halted or reversed polyneuropathy and improved quality of life from baseline in the majority of patients. At baseline, patients in APOLLO had notable autonomic impairment, as demonstrated by the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire autonomic neuropathy domain. At 18 months, patisiran improved autonomic neuropathy symptoms compared with placebo [COMPASS-31, least squares (LS) mean difference, − 7.5; 95% CI: − 11.9, − 3.2; Norfolk QOL-DN autonomic neuropathy domain, LS mean difference, − 1.1; − 1.8, − 0.5], nutritional status (modified body mass index, LS mean difference, 115.7; − 82.4, 149.0), and vasomotor function (postural blood pressure, LS mean difference, − 0.3; − 0.5, − 0.1). Patisiran treatment also led to improvement from baseline at 18 months for COMPASS-31 (LS mean change from baseline, − 5.3; 95% CI: − 7.9, − 2.7) and individual domains, orthostatic intolerance (− 4.6; − 6.3, − 2.9) and gastrointestinal symptoms (− 0.8; − 1.5, − 0.2). Rapid worsening of all study measures was observed with placebo, while patisiran treatment resulted in stable or improved scores compared with baseline. Patisiran demonstrates benefit across a range of burdensome autonomic neuropathy manifestations that deteriorate rapidly without early and continued treatment.
相似文献